GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy

Name: GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy
Rating: 4.8 (40 reviews)

Master the science and clinical applications of GLP-1–based therapies like Ozempic, Wegovy, and Mounjaro

Created byDr. Amogh G Nair

Last updated 9/2025

English

What you'll learn

Explain incretin biology and receptor signaling in diabetes and obesity
Differentiate the mechanisms of GLP-1, GIP, and dual agonist therapies
Analyze multi-organ metabolic effects beyond pancreatic regulation
Evaluate clinical data and therapeutic applications of GLP-1–based drugs

Course content

5 sections • 5 lectures • 50m total length

Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine1:21
Welcome to this course! Here, we’ll explore how incretin-based therapies are reshaping the treatment landscape for diabetes, obesity, and metabolic disorders. You’ll discover the biology behind GLP-1 and GIP, how dual agonists work, and what makes them so powerful. Whether you’re a researcher, student, or clinician, this course will give you both scientific depth and practical insights into therapeutic applications.

Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health10:46
This chapter dives into the foundations of incretin biology. You’ll learn how GLP-1 and GIP hormones regulate glucose homeostasis, insulin secretion, and satiety. We’ll cover receptor signaling mechanisms, cross-talk with other pathways, and how these molecular insights explain the effectiveness of incretin-based therapies.

Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms9:57
Here, we focus on the mechanistic distinctions between GLP-1 receptor agonists, GIP agonists, and dual GIP/GLP-1 agonists. You’ll understand how each pathway contributes to glycemic control, weight reduction, and cardiometabolic improvements. By the end, you’ll be able to explain why dual agonists represent a next-generation therapeutic strategy.

Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects11:21
This chapter expands the discussion to extra-pancreatic effects of GLP-1–based therapies. You’ll explore their role in brain appetite centers, cardiovascular function, gut motility, and liver metabolism. These systemic insights reveal why incretin therapies have broad therapeutic potential, making them relevant far beyond diabetes.

Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs17:15
In this final chapter, you’ll connect science to practice. We’ll review pivotal clinical trials, real-world evidence, and approved GLP-1 receptor agonists on the market. You’ll learn how to critically assess efficacy, safety, and therapeutic applications in obesity, type 2 diabetes, and cardiovascular risk reduction. By the end, you’ll know how to translate scientific mechanisms into clinical relevance.

Requirements

No prior knowledge required

Description

GLP-1 receptor agonists and dual GIP/GLP-1 agonists have transformed the treatment of type 2 diabetes, obesity, and cardiometabolic disorders.

Drugs like Ozempic, Wegovy, and Mounjaro are no longer just glucose-lowering agents; they are reshaping obesity management, cardiovascular risk reduction, and even liver disease therapy.

This course is about GLP-1 & GIP Drugs like Ozempic, Wegovy, and Mounjaro used in Obesity & Diabetes Therapy, and is designed to give you a complete, mechanism-driven understanding of how incretin hormones work, why their biology is so powerful, and how modern therapeutics harness these pathways to benefit the people in need.

You will explore the molecular mechanisms of incretin receptors, pancreatic regulation, and multi-organ effects, and then connect this knowledge to real-world therapeutic applications.

Whether you are in biotech research, pharmacy, medicine, or academia, this course bridges cutting-edge molecular biology with practical pharmacology and clinical insight.

By the end, you’ll be able to:

Explain the physiology of GLP-1 and GIP and their complementary roles in glucose regulation
Understand how receptor signaling differences translate into therapeutic outcomes
Evaluate how incretin therapies impact multiple organs: brain, gut, adipose tissue, and liver
Analyze clinical trial data on HbA1c reduction, weight loss, and cardiovascular protection
Appreciate the evolution from GLP-1 analogues to dual agonists, and where the field is going

Who this course is for:

Biotech and pharmaceutical researchers developing metabolic therapies.
Pharmacy, medical, and life science students seeking therapeutic insights.
Clinicians and pharmacists interested in GLP-1–based treatment strategies.
Healthcare and biotech professionals curious about obesity and diabetes drug innovation.

GLP-1 & GIP Drugs:Ozempic, Wegovy-Obesity & Diabetes Therapy

What you'll learn

Explore related topics

Course content

Chapter 0 – Introduction: Why GLP-1 Therapies Are Transforming Medicine1 lecture • 1min

Chapter 1 – Incretin Biology and Receptor Signaling in Metabolic Health1 lecture • 11min

Chapter 2 – Comparing GLP-1, GIP, and Dual Agonist Mechanisms1 lecture • 10min

Chapter 3 – Beyond the Pancreas: Multi-Organ Metabolic Effects1 lecture • 11min

Chapter 4 – Clinical Evidence and Therapeutic Applications of GLP-1 Drugs1 lecture • 17min

Requirements

Description

Who this course is for: